In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of disease-causing genetic mutations in conditions like epilepsy and ...

A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.

Mark Field joins the DNA sequencing giant after six years at Insulet, which makes devices for people with diabetes.